"bedside to bench" in drug discovery
TRANSCRIPT
ProteoSep® 2D ProteinMicroarray Executive
OverviewDesigned for Drug Hunters and Clinicians
Why Consider Our Proteomics Module?• Easy to insert, at any point, in your drug discovery process.• Designed to generate unique, clinically important data much earlier in the clinical trial
decision making process.• A “Bedside to Bench” approach to drug and clinical biomarker development• A simple means of discovering what we do not know using real patient samples
• Find high probability targets for any disease of interest.• Patient autoantibody signatures serve as the sentinels for targets of interest• Model cell lines serve as the source of targets instead of recombinant proteins – More real protein
expression information utilized.• Clinical relevance of data dictates better/best path forward new and/or existing targets
• Concept works for Biologics and Biosimilars development applications as well.Low cost, precise and fast
High Throughput Process-TBI Example
Culture 10 million cells (highly pure)
Human Neurons Human Astroglia
Detach and Centrifuge to
Pellets
Human Microglia
Processing TBI Patient Samples
100s of Patient Samples (Serum) Provided by
Program Sponsor
Proteostep 2DLiquid Fractionation
App. 2,000 Protein Samples for Arraying
Microarray Printing
Production of Required # of Arrays for Testing Samples
Only a Small Fraction of Samples Prove Clinically
Valid
Cell Lysates
Projects• TBI – 2 projects underway - Confidential• Pain Management - Confidential• Breast cancer – Univ. of Michigan Medical center• Liver cancer/Liver disease – University of Chicago Hospitals• Pancreatic Cancer/Pancreatitis – Univ. of Mich.• Colorectal Cancer - Henry Ford Hospital• Prostate Cancer – University of Michigan• HCP and Biologics development - various companies - confidential
How the Results Can be Used• Drug clinical trial monitoring in parallel to clinical outcome.• Drug treated patients from non-drug treated patients (both sick).• Drug responders from non-responders.• Disease progression (stage, grade, etc. as well as temporal changes).• Identifying differences between cancer and a chronic condition (liver
disease from liver cancer, pancreatitis from pancreatic cancer, etc.)• Population proteomics (before and after exposure – e.g. soldiers
being deployed or worker exposure)• Biologics/Biosimilars purity monitoring and clinical development
Highlights• Protein spots that differentiate the patient populations of interest are
identified (typically < 5% of the total number of spots on the microarray).• The <5% spots can be readily accessed for more detailed analysis of
the proteins present for validation and further research.• Now, biologically important candidate biomarkers are pinpointed before
resorting to more sophisticated techniques.
Low cost, precise and fast
Neuromics’ hStem and Primary Cell Categories• Cancer-Associated Fibroblasts (CAFs) and Cells• Brain Astrocytes• Cardiomyocytes-New• Chondrocytes-New• Endothelial Cells-New• Fibroblasts-New• hNP1™ Human Neural Progenitor & • hN2™ Neuron Discovery Kits• NeuroNet Pure Human Neurons Discovery and HTS Kits• Osteoblasts-New• hMPro™ Human Mesenchymal Progenitors (hMPCs)• Mesenchymal Stem Cells (hMSCs)
Pete ShusterCEO and OwnerDirect Phone: [email protected]